Study of the Level of a Protein Which Could Predict the Development of a Fungal Infection in Patients With Acute Leukemia

Inclusion Criteria : * persons who have provided written consent * Patients with national health insurance cover * Patients with malignant hemopathy who have been treated with chemotherapy able to induce profound neutropenia (PN \< 500 / mm3) lasting more than 10 days. * Patients with malignant hemopathy who have received an autologous bone marrow graft * Patients with severe idiopathic medullar aplasia (PN \< 500 / mm3) who need to be hospitalized for at least 10 consecutive days (with or without treatment with immunosuppressants) Exclusion Criteria: * Patients who have received an bone marrow PSC allograft (as such patients have a risk of aspergillosis, which appears in most cases after medullar recovery; they will not be included in the study). * Patients who have received an autologous PSC graf (as the duration of neutropenia is in most cases less than 10 days). * Patients whose neutropenia, retrospectively assessed, lasted less than 10 days.